```html

Latent Tuberculosis Infection (LTBI)

Overview

Latent tuberculosis infection (LTBI) occurs when a person is infected with Mycobacterium tuberculosis but does not have active disease. The bacteria remain dormant in the body, often for years, without causing symptoms or being contagious. Approximately 1.7 billion people worldwide (≈ 23 % of the global population) are estimated to have LTBI, making it the largest reservoir for future cases of active tuberculosis (TB).<sup>[1] WHO Global TB Report 2023</sup>

LTBI can affect anyone, but certain groups are more likely to be infected:

• People born in or who have lived for an extended period in countries with high TB prevalence (e.g., India, China, South Africa).
• Close contacts of someone with active pulmonary TB.
• Individuals with weakened immune systems (HIV, diabetes, immunosuppressive therapy, malnutrition).
• Health‑care workers, correctional‑facility staff, and others with occupational exposure.

Symptoms

By definition, latent TB does not produce symptoms. However, it is important to recognize the signs of progression to active TB, because early detection dramatically improves outcomes. If any of the following appear, seek evaluation promptly:

• Persistent cough lasting > 2 weeks.
• Unexplained weight loss or loss of appetite.
• Fever (often low‑grade, especially in the evening).
• Night sweats.
• Chest pain or shortness of breath.
• Fatigue that interferes with daily activities.

These symptoms indicate possible active TB and require urgent medical attention.

Causes and Risk Factors

How LTBI Develops

TB spreads through airborne droplets when a person with active pulmonary TB coughs, sneezes, or speaks. Inhalation of 1–10 bacilli can lead to infection. Most healthy adults mount an immune response that walls off the bacteria in granulomas, resulting in a latent state.

Key Risk Factors

• Geographic exposure: Living in or traveling to high‑incidence regions.
• Close contact: Household members, daycare staff, or anyone sharing indoor air with an infectious case.
• Immune compromise: HIV infection (↑ 10‑fold risk), recent organ transplant, biologic therapies (TNF‑α inhibitors), chronic renal failure, malignancy.
• Comorbid conditions: Diabetes mellitus, silicosis, chronic lung disease.
• Age: Children under 5 are more likely to progress to disease once infected.
• Socio‑economic factors: Overcrowding, poor ventilation, malnutrition.

Diagnosis

Because LTBI produces no symptoms, diagnosis relies on tests that detect immune sensitization to TB antigens.

1. Tuberculin Skin Test (TST)

• Also called the Mantoux test.
• 5 IU of purified protein derivative (PPD) is injected intradermally; induration is measured after 48–72 hours.
• Interpretation depends on risk category (e.g., ≥5 mm for HIV‑positive, ≥10 mm for recent contacts, ≥15 mm for low‑risk individuals).
• Limitations: cross‑reactivity with Bacillus Calmette‑Guérin (BCG) vaccine and non‑tuberculous mycobacteria.

2. Interferon‑γ Release Assays (IGRAs)

• Blood tests (QuantiFERON‑TB Gold Plus, T‑SPOT.TB) measuring interferon‑γ released by T‑cells after exposure to TB‑specific antigens (ESAT‑6, CFP‑10).
• Advantages: not affected by BCG vaccination, single patient visit.
• Preferred for:
  • People vaccinated with BCG.
  • Those unlikely to return for TST reading.

3. Chest Radiography

A standard postero‑anterior (PA) chest X‑ray is performed to rule out active pulmonary disease before initiating LTBI treatment. Normal findings support a latent diagnosis.

4. Additional Tests (if indicated)

• CT scan for atypical radiographic findings.
• Sputum smear, culture, or nucleic‑acid amplification test (NAAT) if active TB is suspected.

Treatment Options

Effective treatment eliminates dormant bacilli and reduces the risk of future active disease by 60‑90 %. Choice of regimen is guided by drug‑susceptibility patterns, patient comorbidities, and likelihood of adherence.

First‑Line Regimens (per CDC & WHO)

1. Isoniazid (INH) for 6–9 months – classic regimen; 300 mg daily (or 900 mg weekly) with pyridoxine (vitamin B6) 25–50 mg daily to prevent peripheral neuropathy.
2. Isoniazid + Rifapentine (3HP) – 12 once‑weekly doses under direct observation or self‑administration. Shorter course improves completion rates.
3. Rifampin (RIF) for 4 months – 600 mg daily; alternative for patients who cannot tolerate INH.
4. Isoniazid + Rifampin (3HR) – 3 months of daily combined therapy; used when weekly dosing is not feasible.

Special Situations

• HIV‑positive individuals: 9‑month INH regimen is preferred; rifamycin‑based regimens may interact with antiretrovirals.
• Pregnancy: INH alone (9 months) is considered safe; avoid rifampin‑based weekly regimens unless benefits outweigh risks.
• Drug‑resistant TB exposure: Consult a specialist; may require fluoroquinolone‑based prophylaxis.

Monitoring & Adherence

Baseline liver function tests (LFTs) are recommended for patients > 35 years, those with pre‑existing liver disease, or chronic alcohol use. Follow‑up LFTs are repeated if symptoms of hepatotoxicity develop (e.g., nausea, jaundice, dark urine). Directly observed therapy (DOT) or digital adherence technologies (mobile apps, video DOT) improve completion rates.

Living with Latent Tuberculosis Infection

Having LTBI does not mean you are ill, but it does require ongoing attention.

• Medication adherence: Set daily alarms, use pillboxes, or enlist a support person.
• Know side‑effects: Nausea, mild rash, fatigue are common; seek care if you notice dark urine, persistent vomiting, or severe rash.
• Maintain a healthy lifestyle: Balanced diet, adequate sleep, regular exercise, and avoidance of excess alcohol support immune health.
• Vaccinations: Keep up to date with influenza, COVID‑19, and pneumococcal vaccines, as respiratory infections can exacerbate TB risk.
• Inform health‑care providers: Always tell doctors you have LTBI before starting new medications (especially hepatotoxic drugs).
• Travel considerations: When traveling to high‑TB‑burden areas, avoid prolonged close contact with people known to have active TB and ensure good ventilation in crowded settings.

Prevention

Preventing LTBI and its progression to active disease is a public‑health priority.

• Identify and treat contacts: Prompt screening of household members and close contacts of active TB cases.
• BCG vaccination: Provides limited protection against severe pediatric TB; not routinely used in low‑incidence countries but may be recommended for high‑risk travelers.
• Infection control in health‑care settings: Use N95 respirators, negative‑pressure rooms, and UV germicidal irradiation where feasible.
• Address modifiable risk factors: Control diabetes, reduce tobacco use, improve nutrition, and manage HIV effectively.
• Screen high‑risk populations: Annual IGRA/TST for people on TNF‑α inhibitors, dialysis patients, and recent immigrants from high‑incidence regions.

Complications

If LTBI is left untreated, the main complication is progression to active TB, which carries significant morbidity and mortality.

• Active pulmonary TB: Cough, hemoptysis, lung cavitation, and contagiousness.
• Extrapulmonary TB: Meningitis, lymphadenitis, osteoarticular disease, or disseminated miliary TB, which are more common in immunocompromised hosts.
• Drug‑induced liver injury: Particularly with INH or rifampin; severe hepatitis, though rare, can be life‑threatening.
• Treatment failure or resistance: Incomplete or irregular therapy can foster drug‑resistant TB strains.

When to Seek Emergency Care

---

References

1. World Health Organization. Global Tuberculosis Report 2023. WHO; 2023.
2. Centers for Disease Control and Prevention. Tuberculosis (TB) – Latent TB Infection (LTBI). CDC; 2024.
3. Mayo Clinic. Latent tuberculosis infection. Updated 2024.
4. Cleveland Clinic. Treatment of latent tuberculosis infection. 2023.
5. National Institute of Allergy and Infectious Diseases. Guidelines for the treatment of latent TB infection. 2023.

```